Danaher Acquires UK Biotech Company Abcam

The transaction was unanimously approved and recommended by the Abcam board of directors and unanimously approved by the Danaher board of directors.

Founded in 1998, Abcam offers the scientific community a wide range of extensively validated antibodies, reagents, biomarkers, and assays. These resources serve to target key biological pathways critical for the advancement of drug discovery, life sciences research, and diagnostics. The company's technologies find application among approximately 750,000 researchers. Under the planned arrangement, Abcam is poised to continue operating as an independent entity and brand within Danaher's Life Sciences sector. The acquisition of Abcam reflects Danaher's strategy to contribute towards mapping complex diseases and accelerating the process of drug discovery.

“Our strategy has transformed Abcam to become a scale innovator and important catalyst in the global life science community,” said Alan Hirzel, Chief Executive Officer of Abcam. “Danaher shares our passion to help life science researchers achieve their mission faster and their operating company model allows us to continue to pursue our strategy, while harnessing the power of the Danaher Business System to ensure we remain the partner of choice for our customers.”

“We couldn’t be more excited to have Abcam join Danaher,” added Rainer M. Blair, President and Chief Executive Officer, Danaher. “Abcam’s long track record of innovation, outstanding product quality and breadth of antibody portfolio positions them as a key partner for the scientific community. We look forward to welcoming Abcam’s innovative and talented team to Danaher as we continue to help our customers solve some of the world’s biggest healthcare challenges."

Related Links:
Danaher Corporation 
Abcam plc